-+ 0.00%
-+ 0.00%
-+ 0.00%
According to Fuan Pharmaceutical's announcement, the company's wholly-owned subsidiary Fuan Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. has been newly included in the 2026 edition of the national medical insurance catalogue. The medical insurance classification is Class B, the payment standard for 30 mg/bag is 4.02 yuan, and the payment standard for 50 mg/bag is 5.94 yuan. The payment standard is valid from January 1, 2027 to December 31, 2028. The drug is suitable for various types of infectious diseases caused by sensitive bacteria. Inclusion in medical insurance is beneficial to product market development. It is not expected to have a significant impact on the company's current business performance, and there is uncertainty about future sales.
Share
Listen to the news
According to Fuan Pharmaceutical's announcement, the company's wholly-owned subsidiary Fuan Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. has been newly included in the 2026 edition of the national medical insurance catalogue. The medical insurance classification is Class B, the payment standard for 30 mg/bag is 4.02 yuan, and the payment standard for 50 mg/bag is 5.94 yuan. The payment standard is valid from January 1, 2027 to December 31, 2028. The drug is suitable for various types of infectious diseases caused by sensitive bacteria. The inclusion of medical insurance is beneficial to product market development. It is not expected to have a significant impact on the company's current business performance, and there is uncertainty about future sales.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending